Kissei Pharmaceutical News and Activities
Presence
Kissei Pharmaceutical develops, manufactures, and sells medicines and related healthcare products. Its main products include prescription drugs and specialty therapies for hospitals, clinics, and patients in Japan and international markets.
Kissei Pharmaceutical products and services overview:
- Prescription drugs
- Specialty medicines
- Urology treatments
- Kidney care
- Bone health
- Healthcare products
Revenue: ~$545 million
Employees: 1,700
Headquarters: Matsumoto, Japan
Kissei Pharmaceutical is one of the...
Kissei Pharmaceutical is a company listed under the stock ticker 4547 (JP).
Executives
View the org chart displaying its 19 main executives
Most searched biographies at Kissei Pharmaceutical
- Mutsuo Kanzawa, Chairman of the Board, Chief Executive Officer and...
- Yoshinori Otsuki, Outside Director
- Minoru Nomura, Director
Create your alert
to follow the executive moves at Kissei Pharmaceutical.
Pharmaceuticals
Kissei Pharmaceutical has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Kissei Pharmaceutical
- Financial results/Timely disclosure | Investor Relations | English Home | KISSEI PHARMACEUTICAL CO.,LTD.Back ButtonSearch IconFilter Icon
- Licensing Agreement for
- Notice Regarding Sale of Investment Securities (Result)
- Notice Concerning Revisions to Financial Results Forecast and Recording of Extraordinary Income
- Licensing Agreement with Viridian Therapeutics for
- Notice Regarding Completion of Disposal of Treasury Stocks as Restricted Stock for Members of the Board and Corporate Officers
- New Launch of TAVALISSE® for Chronic Idiopathic Thrombocytopenic Purpura Treatment in South Korea
- Notice Concerning Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers
- Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System (ToSTNeT-3), the Completion of Acquisition of Treasury shares and the Cancellation of Treasury Shares
- Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3) and the Cancellation of Treasury Shares
- View more press releases Close
Social media about Kissei Pharmaceutical
- Kissei Pharmaceutical on Wikipedia, Google News & Yahoo Finance
- Kissei Pharmaceutical on LinkedIn, X (Twitter) & YouTube
